Workflow
HUAPONT LIFE SCIENCES(002004)
icon
Search documents
华邦健康(002004.SZ):2025年中报净利润为3.88亿元、较去年同期上涨23.90%
Xin Lang Cai Jing· 2025-08-20 01:49
Core Insights - Company reported a total operating revenue of 5.945 billion, an increase of 22.99 million compared to the same period last year, marking a year-on-year growth of 0.39% [1] - Net profit attributable to shareholders reached 388 million, up by 74.93 million year-on-year, reflecting a growth of 23.90% [1] - Net cash inflow from operating activities was 537 million, an increase of 169 million year-on-year, representing a growth of 46.10% [1] Financial Ratios - The latest debt-to-asset ratio stands at 46.17%, a decrease of 1.14 percentage points from the previous quarter and a decrease of 1.57 percentage points from the same period last year [3] - The latest gross profit margin is 36.28% [4] - Return on equity (ROE) is 3.98%, an increase of 0.84 percentage points compared to the same period last year [4] Earnings and Efficiency Metrics - Diluted earnings per share are 0.20 yuan, an increase of 0.04 yuan year-on-year, reflecting a growth of 24.15% [5] - Total asset turnover ratio is 0.20 times, an increase of 0.01 times year-on-year, representing a growth of 5.07% [5] - Inventory turnover ratio is 1.71 times, an increase of 0.26 times year-on-year, marking a growth of 17.96% [5] Shareholder Information - The number of shareholders is 73,800, with the top ten shareholders holding 736 million shares, accounting for 37.18% of the total share capital [6]
华邦健康上半年净利增长23%,64岁董事长张松山博士学历、年薪195万
Sou Hu Cai Jing· 2025-08-20 01:47
瑞财经 刘治颖 8月19日,华邦健康(SZ002004)发布2025年半年度报告,营收净利双增。 2025年上半年,华邦健康实现营业收入59.45亿元,同比增长0.39%;归属于上市公司股东的净利润3.88亿元,同比增长23.9%;归属 于上市公司股东的扣除非经常性损益的净利润3.48亿元,同比增长17.62%。 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入(元) | 5, 945, 032, 088. 09 | 5, 922, 042, 354. 85 | 0. 39% | | 归属于上市公司股东的净利润(元) | 388, 455, 625, 50 | 313, 522, 665, 65 | 23.90% | | 归属于上市公司股东的扣除非经常性损 益的净利润(元) | 347,597, 224. 74 | 295, 534, 853, 91 | 17.62% | | 经营活动产生的现金流量净额(元) | 536, 502, 508, 00 | 367, 219, 592, 32 | 46. 10% | | 基本每股收益( ...
华邦生命健康股份有限公司2025年半年度报告摘要
Core Viewpoint - The company has proposed a mid-term profit distribution plan for 2025, which includes a cash dividend of 2.00 yuan per 10 shares, based on a total share capital of 1,972,852,683 shares after deducting repurchased shares [7][34]. Company Overview - The company is named Huabang Life Health Co., Ltd. and is listed under the stock code 002004 [1]. - The company has not undergone any changes in its controlling shareholder or actual controller during the reporting period [6]. Financial Data and Indicators - For the first half of 2025, the company reported a net profit attributable to shareholders of 388,455,625.50 yuan, with available profits for distribution amounting to 775,936,281.82 yuan [7][8]. - The total profit available for distribution as per the consolidated financial statements is 1,986,457,656.65 yuan [7]. Profit Distribution Plan - The profit distribution plan includes a cash dividend of 394,570,536.60 yuan (including tax), with no stock dividends or capital reserve transfers [8][9]. - The plan is designed to enhance the company's investment value and share the growth results with investors, ensuring that it does not affect the company's liquidity or debt repayment capacity [9]. Shareholder Meeting - The company will hold its first extraordinary general meeting of 2025 on September 5, 2025, to review the proposed profit distribution plan [12][15]. - The meeting will be conducted both in-person and via online voting, with a registration deadline of September 2, 2025 [15][16]. Performance Presentation - The company will hold a performance presentation on August 26, 2025, to further inform investors about its operational status for the first half of 2025 [30][31]. - Investors are encouraged to submit questions in advance to enhance the relevance of the discussion during the presentation [31].
华邦健康:多领域协同发力 上半年业绩实现稳步提升
Core Insights - Company reported a revenue of 5.945 billion yuan for the first half of 2025, a year-on-year increase of 0.39%, and a net profit attributable to shareholders of 388 million yuan, a significant increase of 23.9% [1] - The company plans to distribute a cash dividend of 2 yuan per 10 shares, reflecting its commitment to shareholder returns [1] - The company has established a diversified structure with a focus on the health industry, covering five major sectors: pharmaceuticals, medical services, agrochemicals, new materials, and tourism [1] Pharmaceutical Sector - The company has strengthened its R&D investment, with several products receiving approvals, including the first generic version of calcipotriol betamethasone ointment, marking a significant breakthrough in psoriasis treatment [2] - The company is consolidating its prescription market advantage while actively expanding into domestic and overseas raw material markets, and has launched functional skincare products to enhance its product matrix [2] Medical Sector - The company has added new specialty clinics in its Chongqing Songshan Hospital, enhancing its medical service capabilities and achieving steady growth in consumer healthcare and health management [2] - The Beijing Huasheng Rehabilitation Hospital has increased its bed capacity to 457, with a steady rise in patient visits and solid progress in key rehabilitation disciplines [2] Agrochemical Sector - The agrochemical sector is experiencing a recovery in profitability due to improved supply-demand dynamics and price increases in certain product segments [3] - The company’s agrochemical business is stabilizing and contributing to overall performance growth [3] New Materials Sector - The new materials sector has seen an increase in orders and improved gross margins due to recovering demand and cost advantages [3] Tourism Sector - The tourism sector continues to show steady improvement, with the company actively seizing industry opportunities and enhancing market competitiveness [3] Strategic Focus - The company aims to continue developing a full industry chain model centered on "big health," integrating raw materials, formulations, functional skincare, health management, and medical services for sustainable long-term growth [3]
小米集团二季度、泡泡玛特上半年净利同比大增丨公告精选
Group 1: Company Performance - Xiaomi Group reported total revenue of 116 billion yuan for Q2 2025, a year-on-year increase of 30.5%, with adjusted net profit of 10.8 billion yuan, up 75.4% [1] - Pop Mart achieved revenue of 13.88 billion yuan in the first half of the year, a significant year-on-year growth of 204.4%, with adjusted net profit of 4.71 billion yuan, up 362.8% [2] - Xian Da Co. reported a net profit of 136 million yuan for the first half of 2025, a staggering year-on-year increase of 2561.58%, with revenue of 1.423 billion yuan, up 11.82% [3] - Huabang Health's net profit increased by 23.90% in the first half of the year [14] - Fuyao Glass's net profit grew by 37% in the first half of the year [14] - Jibite's net profit rose by 24.50% in the first half of the year, with a proposed dividend of 66 yuan for every 10 shares [14] - Meihua Biotech's net profit increased by 19.96% in the first half of the year [14] - Tiancheng Technology's net profit saw a slight increase of 0.22% in the first half of the year [14] - Zoli Pharmaceutical's net profit grew by 26.16% in the first half of the year [14] - Yuyin Co.'s net profit increased by 10.43% in the first half of the year [14] - Nuo Ping's net profit rose by 17.35% in the first half of the year [14] - Jinli Permanent Magnet's net profit surged by 155% in the first half of the year, proposing a dividend of 1.8 yuan for every 10 shares [14] - Huacheng Film's net profit increased by 65.05% in the first half of the year [14] - YTO Express reported a 12.08% year-on-year increase in express product revenue in July [14] - Zhongxin Special Steel's net profit for the first half of the year was 2.798 billion yuan, up 2.67% [14] Group 2: Corporate Actions - Dongjie Intelligent announced plans for a change in control, leading to a temporary suspension of its stock and convertible bonds [4] - Dameng Data's general manager is under investigation, but the company expects no significant impact on operations [5] - Jiangte Electric announced that its subsidiary Yichun Silver Lithium will resume production soon after equipment maintenance [6] - Garden Shares clarified that it does not have a controlling relationship with Yunzhin Technology, which is still in the early stages of technology commercialization [7] - Daikin Heavy Industries completed the delivery of all monopile products for the Nordseecluster offshore wind farm project, which is the largest offshore wind farm under construction in Germany [8] - Zhongyin Securities plans to increase capital by 1.4 billion yuan to its wholly-owned subsidiary Zhongyin International Investment [13] - Xinhongye intends to acquire 62% of Yangzhou Shuguang Optoelectronic Control Co., Ltd. [16] - A joint venture led by Tongyuan Environment won a bid for the expansion project of the sewage treatment plant in Anhui Qimen Economic Development Zone [17]
华邦健康:关于召开2025年第一次临时股东会的通知
Zheng Quan Ri Bao· 2025-08-19 13:43
(文章来源:证券日报) 证券日报网讯 8月19日晚间,华邦健康发布公告称,公司将于2025年9月5日召开2025年第一次临时股东 会。本次股东会将审议《2025年中期利润分配预案》。 ...
华邦健康:第九届董事会第二次会议决议公告
Zheng Quan Ri Bao· 2025-08-19 13:41
证券日报网讯 8月19日晚间,华邦健康发布公告称,公司第九届董事会第二次会议审议通过了《关于召 开2025年第一次临时股东会的议案》等多项议案。 (文章来源:证券日报) ...
华邦健康:2025年半年度净利润同比增长23.90%
证券日报网讯 8月19日晚间,华邦健康发布2025年半年度报告摘要称,2025年半年度公司实现营业收入 为5,945,032,088.09元,同比增长0.39%;实现归属于上市公司股东的净利润为388,455,625.50 元,同比增长23.90%。 (编辑 任世碧) ...
华邦健康2025半年度拟派3.95亿元红包
公司上市以来历次分配方案一览 注:本文系新闻报道,不构成投资建议,股市有风险,投资需谨慎。 (文章来源:证券时报网) 资金面上看,该股今日主力资金净流出243.59万元,近5日主力资金净流入4078.61万元。 两融数据显示,该股最新融资余额为3.74亿元,近5日增加2327.96万元,增幅为6.65%。 按申万行业统计,华邦健康所属的医药生物行业共有15家公司公布了2025半年度分配方案,派现金额最 多的是药明康德,派现金额为10.03亿元,其次是华润三九、白云山,派现金额分别为7.51亿元、6.50亿 元。(数据宝) 2025半年度医药生物行业分红排名 | 代码 | 简称 | 每10股送转 | 每10股派现 | 派现金额(万 | 派现占净利润比例 | 股息率 | | --- | --- | --- | --- | --- | --- | --- | | | | (股) | (元) | 元) | (%) | (%) | | 603259 | 药明康 德 | 0.00 | 3.5 | 100308.38 | 11.72 | 0.58 | | 000999 | 华润三 九 | 0.00 | 4.5 | 7513 ...
华邦健康上半年净利3.88亿元,同比增长23.9%
Bei Jing Shang Bao· 2025-08-19 10:47
资料显示,华邦健康成立于1992年,是国内皮肤临床用药及皮肤健康领域企业,经过三十多年的耕耘, 形成了以大健康产业为核心,农化、新材料、旅游三家上市公司独立发展的模式。目前公司业务范围涵 盖医药、医疗、农化、新材料、旅游等五大领域,旗下共控股三家上市公司,分别为颖泰生物 (920819.BJ)、凯盛新材(301069.SZ)、丽江股份(002033.SZ)。 北京商报讯(记者 丁宁)8月19日晚间,华邦健康(002004)披露半年报显示,公司上半年实现营业收 入59.45亿元,同比增长0.39%;归属净利润3.88亿元,同比增长23.9%。 ...